Jie-Bin Lew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jie-Bin Lew has a total of 242 co-authors. Here are the top co-authors by number of shared publications:
- Megan A. Smith
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
24 shared publications Karen Canfell
Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW
22 shared publications- Karen Canfell
School of Public Health, The University of Sydney, Sydney, Australia
18 shared publications - Kate Therese Simms
Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, NSW, Australia
13 shared publications - Eleonora Feletto
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
10 shared publications - Karen Canfell
Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, Australia
9 shared publications
Latest Publications
- Open Access
- 20 November 2025
- Published by SAGE Publications in Medical Decision Making
- Vol. 46 (2) , 189-201
A New Integrative Modeling Approach for Generating Counterfactual Projections of Colorectal Cancer Incidence Rates in the Absence of Organized Screening in Australia
Background: The Australian National Bowel Cancer Screening Program (NBCSP), which provides 2-yearly screening to people aged 50 to 74 y, had a phased rollout from 2006 and was fully implemented in 2020. To measure the effectiveness of the NBCSP accounting for age-specific trends, we aimed to develop a novel integrative method to project colorectal cancer (CRC) incidence rates from 2006 to 2045 in the absence of the NBCSP (referred to as “no-NBCSP projections”) while addressing the challenge of complex age-specific trends in CRC incidence. Methods: We constructed a new dataset by replacing the observed data for NBCSP-eligible individuals aged 50 to 74 y with intermediate projections based on pre-NBCSP data from 1982 to 2005. We compared the no-NBCSP CRC incidence projected using a standard age-period-cohort (APC) model, age-stratified APC models, and the integrative modeling approach. Results: The integrative modeling approach captured complex age-specific trends better than the standard and age-stratified APC models did. Without the NBCSP, the overall CRC incidence rates would be expected to decline from 2005 to 2025, followed by increases from 2026 to 2045. The incidence rates for those aged <50 y would be projected to continue increasing to 2045, and an increase in incidence rates for older age groups would be projected to occur from 2020 for ages 50 to 54 y, from 2030 for ages 65 to 74 y, and from 2035 for ages 75 y and older. Conclusions: These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia, and they have been used as new calibration targets for a simulation model of CRC and screening in Australia. The methods developed here could be used to generate comparators to assess the impact of other public health interventions. Highlights: We constructed counterfactual projections of colorectal cancer (CRC) incidence rates in the absence of the National Bowel Cancer Screening Program (no-NBCSP projections). To do this, we developed a new integrative modeling approach to capture complex age-specific colorectal cancer incidence trends. These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia. These projections stress the need for ongoing assessment of the starting age for the NBCSP, to tackle the increasing incidence for people younger than 50 y.
- 20 November 2025
- Published by SAGE Publications in Medical Decision Making
- Vol. 46 (2) , 189-201
Open AccessA New Integrative Modeling Approach for Generating Counterfactual Projections of Colorectal Cancer Incidence Rates in the Absence of Organized Screening in Australia
Background: The Australian National Bowel Cancer Screening Program (NBCSP), which provides 2-yearly screening to people aged 50 to 74 y, had a phased rollout from 2006 and was fully implemented in 2020. To measure the effectiveness of the NBCSP accounting for age-specific trends, we aimed to develop a novel integrative method to project colorectal cancer (CRC) incidence rates from 2006 to 2045 in the absence of the NBCSP (referred to as “no-NBCSP projections”) while addressing the challenge of complex age-specific trends in CRC incidence. Methods: We constructed a new dataset by replacing the observed data for NBCSP-eligible individuals aged 50 to 74 y with intermediate projections based on pre-NBCSP data from 1982 to 2005. We compared the no-NBCSP CRC incidence projected using a standard age-period-cohort (APC) model, age-stratified APC models, and the integrative modeling approach. Results: The integrative modeling approach captured complex age-specific trends better than the standard and age-stratified APC models did. Without the NBCSP, the overall CRC incidence rates would be expected to decline from 2005 to 2025, followed by increases from 2026 to 2045. The incidence rates for those aged <50 y would be projected to continue increasing to 2045, and an increase in incidence rates for older age groups would be projected to occur from 2020 for ages 50 to 54 y, from 2030 for ages 65 to 74 y, and from 2035 for ages 75 y and older. Conclusions: These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia, and they have been used as new calibration targets for a simulation model of CRC and screening in Australia. The methods developed here could be used to generate comparators to assess the impact of other public health interventions. Highlights: We constructed counterfactual projections of colorectal cancer (CRC) incidence rates in the absence of the National Bowel Cancer Screening Program (no-NBCSP projections). To do this, we developed a new integrative modeling approach to capture complex age-specific colorectal cancer incidence trends. These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia. These projections stress the need for ongoing assessment of the starting age for the NBCSP, to tackle the increasing incidence for people younger than 50 y.
- Open Access
- 17 February 2025
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 7
Re-evaluating population-level screening recommendations to address increasing early-onset colorectal cancer rates in Australia: a modelling study
- 17 February 2025
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 7
Open AccessRe-evaluating population-level screening recommendations to address increasing early-onset colorectal cancer rates in Australia: a modelling study
- Open Access
- 6 February 2025
- Published by SAGE Publications in Medical Decision Making
- Vol. 45 (3) , 257-275
Recalibrating an Established Microsimulation Model to Capture Trends and Projections of Colorectal Cancer Incidence and Mortality
Background: Changing colorectal cancer (CRC) incidence rates, including recent increases for people younger than 50 y, need to be considered in planning for future cancer control and screening initiatives. Reliable estimates of the impact of changing CRC trends on the National Bowel Cancer Screening Program (NBCSP) are essential for programmatic planning in Australia. An existing microsimulation model of CRC, Policy1-Bowel , was updated to reproduce Australian CRC trends data and provide updated projections of CRC- and screening-related outcomes to inform clinical practice guidelines for the prevention of CRC. Methods: Policy1-Bowel was recalibrated to reproduce statistical age-period-cohort model trends and projections of CRC incidence for 1995–2045 in the absence of the NBCSP as well as published data on CRC incidence trends, stage distribution, and survival in 1995–2020 in Australia. The recalibrated Policy1-Bowel predictions were validated by comparison with published Australian CRC mortality trends for 1995–2015 and statistical projections to 2040. Metamodels were developed to aid the calibration process and significantly reduce the computational burden. Results: Policy1-Bowel was recalibrated, and best-fit parameter sets were identified for lesion incidence, CRC stage progression rates, detection rates, and survival rates by age, sex, bowel location, cancer stage, and birth year. The recalibrated model was validated and successfully reproduced observed CRC mortality rates for 1995–2015 and statistical projections for 2016–2030. Conclusion: The recalibrated Policy1-Bowel model captures significant additional detail on the future incidence and mortality burden of CRC in Australia. This is particularly relevant as younger cohorts with higher CRC incidence rates approach screening ages to inform decision making for these groups. The metamodeling approach allows fast recalibration and makes regular updates to incorporate new evidence feasible. Highlights: In Australia, colorectal cancer incidence rates are increasing for people younger than 50 y but decreasing for people older than 50 y, and colorectal cancer survival is improving as new treatment technologies emerge. To evaluate the future health and economic impact of screening and inform policy, modeling must include detailed trends and projections of colorectal cancer incidence, mortality, and diagnosis stage. We used novel techniques including integrative age-period cohort projections and metamodel calibration to update Policy1-Bowel , a detailed microsimulation of colorectal cancer and screening in Australia.
- 6 February 2025
- Published by SAGE Publications in Medical Decision Making
- Vol. 45 (3) , 257-275
Open AccessRecalibrating an Established Microsimulation Model to Capture Trends and Projections of Colorectal Cancer Incidence and Mortality
Background: Changing colorectal cancer (CRC) incidence rates, including recent increases for people younger than 50 y, need to be considered in planning for future cancer control and screening initiatives. Reliable estimates of the impact of changing CRC trends on the National Bowel Cancer Screening Program (NBCSP) are essential for programmatic planning in Australia. An existing microsimulation model of CRC, Policy1-Bowel , was updated to reproduce Australian CRC trends data and provide updated projections of CRC- and screening-related outcomes to inform clinical practice guidelines for the prevention of CRC. Methods: Policy1-Bowel was recalibrated to reproduce statistical age-period-cohort model trends and projections of CRC incidence for 1995–2045 in the absence of the NBCSP as well as published data on CRC incidence trends, stage distribution, and survival in 1995–2020 in Australia. The recalibrated Policy1-Bowel predictions were validated by comparison with published Australian CRC mortality trends for 1995–2015 and statistical projections to 2040. Metamodels were developed to aid the calibration process and significantly reduce the computational burden. Results: Policy1-Bowel was recalibrated, and best-fit parameter sets were identified for lesion incidence, CRC stage progression rates, detection rates, and survival rates by age, sex, bowel location, cancer stage, and birth year. The recalibrated model was validated and successfully reproduced observed CRC mortality rates for 1995–2015 and statistical projections for 2016–2030. Conclusion: The recalibrated Policy1-Bowel model captures significant additional detail on the future incidence and mortality burden of CRC in Australia. This is particularly relevant as younger cohorts with higher CRC incidence rates approach screening ages to inform decision making for these groups. The metamodeling approach allows fast recalibration and makes regular updates to incorporate new evidence feasible. Highlights: In Australia, colorectal cancer incidence rates are increasing for people younger than 50 y but decreasing for people older than 50 y, and colorectal cancer survival is improving as new treatment technologies emerge. To evaluate the future health and economic impact of screening and inform policy, modeling must include detailed trends and projections of colorectal cancer incidence, mortality, and diagnosis stage. We used novel techniques including integrative age-period cohort projections and metamodel calibration to update Policy1-Bowel , a detailed microsimulation of colorectal cancer and screening in Australia.
- 30 March 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (3) , 558-568
Access to colorectal cancer screening in populations in China, 2020: A coverage‐focused synthesis analysis
In populations in China, colorectal cancer (CRC) screening can be mainly accessed through organized screening, opportunistic screening, and physical examination. This screening intervention is found to be effective but the exact coverage rate is difficult to measure. Based on data from published articles, official websites, and available program reports, the screening coverage rate and related indicators were quantified. A rapid review was then conducted to estimate the overall and the breakdown coverage rates of the sub‐type screening services, by leveraging the numbers of articles and the by‐type median sample sizes. Up to 2020, two central government‐funded and four provincial/municipal‐level organized CRC screening programs have been initiated and included in this analysis. For populations aged 40–74, the estimated coverage rate of organized programs in China was 2.7% in 2020, and the 2‐year cumulative coverage rate in 2019–2020 was 5.3% and the 3‐year cumulative coverage rate in 2018–2020 was 7.7%. The corresponding coverage rates of 50–74‐year‐olds were estimated to be 3.4%, 7.1%, and 10.3%, respectively. Based on the rapid review approach, the overall screening coverage rate for 40–74 years, considering organized screening programs, opportunistic screening, and physical examinations, was then estimated to be 3.0% in China in 2020. However, comparing the findings of this study with the number of health check‐ups reported in the local national health statistics yearbooks suggests that the number of CRC physical examinations may be underestimated in this study. The findings suggest that further efforts are needed to improve population access to CRC screening in China. Furthermore, evidence for access to opportunistic CRC screening and physical examination is limited, and more quantitative investigation is needed.
- 30 March 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (3) , 558-568
Access to colorectal cancer screening in populations in China, 2020: A coverage‐focused synthesis analysis
In populations in China, colorectal cancer (CRC) screening can be mainly accessed through organized screening, opportunistic screening, and physical examination. This screening intervention is found to be effective but the exact coverage rate is difficult to measure. Based on data from published articles, official websites, and available program reports, the screening coverage rate and related indicators were quantified. A rapid review was then conducted to estimate the overall and the breakdown coverage rates of the sub‐type screening services, by leveraging the numbers of articles and the by‐type median sample sizes. Up to 2020, two central government‐funded and four provincial/municipal‐level organized CRC screening programs have been initiated and included in this analysis. For populations aged 40–74, the estimated coverage rate of organized programs in China was 2.7% in 2020, and the 2‐year cumulative coverage rate in 2019–2020 was 5.3% and the 3‐year cumulative coverage rate in 2018–2020 was 7.7%. The corresponding coverage rates of 50–74‐year‐olds were estimated to be 3.4%, 7.1%, and 10.3%, respectively. Based on the rapid review approach, the overall screening coverage rate for 40–74 years, considering organized screening programs, opportunistic screening, and physical examinations, was then estimated to be 3.0% in China in 2020. However, comparing the findings of this study with the number of health check‐ups reported in the local national health statistics yearbooks suggests that the number of CRC physical examinations may be underestimated in this study. The findings suggest that further efforts are needed to improve population access to CRC screening in China. Furthermore, evidence for access to opportunistic CRC screening and physical examination is limited, and more quantitative investigation is needed.
- Open Access
- 19 December 2023
- Published by Wiley in Cancer Medicine
- Vol. 13 (1)
Estimating the economic burden of colorectal cancer in China, 2019–2030: A population‐level prevalence‐based analysis
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. Comprehensive data on the economic burden of CRC at a population‐level is critical in informing policymaking, but such data are currently limited in China.Methods: From a societal perspective, the economic burden of CRC in 2019 was estimated, including direct medical and nonmedical expenditure, disability, and premature‐death‐related indirect expenditure. Data on disease burden was taken from the GBD 2019 and analyzed using a prevalence‐based approach. The per‐person direct expenditure and work loss days were from a multicenter study; the premature‐death‐related expenditure was estimated using a human capital approach. Projections were conducted in different simulated scenarios. All expenditure data were in Chinese Yuan (CNY) and discounted to 2019.Results: In 2019, the estimated overall economic burden of CRC in China was CNY170.5 billion (0.189% of the local GDP). The direct expenditure was CNY106.4 billion (62.4% of the total economic burden), 91.4% of which was a direct medical expenditure. The indirect expenditure was CNY64.1 billion, of which 63.7% was related to premature death. The predicted burden would reach CNY560.0 billion in 2030 given constant trends for disease burden; however, it would be alternatively reduced to <CNY515.2 billion if the cancer prevention and control goals set by the United Nations and China for 2030 are achieved.Conclusions: The population‐level economic burden of CRC in China in 2019 seemed noteworthy, with the direct expenditure accounting for more than half. Without effectively reducing exposure to modifiable factors and expanding screening coverage, the burden would continue increasing.
- 19 December 2023
- Published by Wiley in Cancer Medicine
- Vol. 13 (1)
Open AccessEstimating the economic burden of colorectal cancer in China, 2019–2030: A population‐level prevalence‐based analysis
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. Comprehensive data on the economic burden of CRC at a population‐level is critical in informing policymaking, but such data are currently limited in China.Methods: From a societal perspective, the economic burden of CRC in 2019 was estimated, including direct medical and nonmedical expenditure, disability, and premature‐death‐related indirect expenditure. Data on disease burden was taken from the GBD 2019 and analyzed using a prevalence‐based approach. The per‐person direct expenditure and work loss days were from a multicenter study; the premature‐death‐related expenditure was estimated using a human capital approach. Projections were conducted in different simulated scenarios. All expenditure data were in Chinese Yuan (CNY) and discounted to 2019.Results: In 2019, the estimated overall economic burden of CRC in China was CNY170.5 billion (0.189% of the local GDP). The direct expenditure was CNY106.4 billion (62.4% of the total economic burden), 91.4% of which was a direct medical expenditure. The indirect expenditure was CNY64.1 billion, of which 63.7% was related to premature death. The predicted burden would reach CNY560.0 billion in 2030 given constant trends for disease burden; however, it would be alternatively reduced to <CNY515.2 billion if the cancer prevention and control goals set by the United Nations and China for 2030 are achieved.Conclusions: The population‐level economic burden of CRC in China in 2019 seemed noteworthy, with the direct expenditure accounting for more than half. Without effectively reducing exposure to modifiable factors and expanding screening coverage, the burden would continue increasing.
- Open Access
- 6 April 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia
Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services, the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel, and cervical cancer screening programmes on cancer outcomes and cancer services. We used the Policy1 modelling platforms to predict outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9, and 12 mo. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. We found that a 12-mo screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020–2021) and colorectal cancer (up to 12.1% reduction over 2020–21), and increase cervical cancer diagnoses (up to 3.6% over 2020–2022), with upstaging expected for these cancer types (2, 1.4, and 6.8% for breast, cervical, and colorectal cancers, respectively). Findings for 6–12-mo disruption scenarios illustrate that maintaining screening participation is critical to preventing an increase in the burden of cancer at a population level. We provide programme-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programmes and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions.
- 6 April 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessA modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia
Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services, the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel, and cervical cancer screening programmes on cancer outcomes and cancer services. We used the Policy1 modelling platforms to predict outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9, and 12 mo. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. We found that a 12-mo screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020–2021) and colorectal cancer (up to 12.1% reduction over 2020–21), and increase cervical cancer diagnoses (up to 3.6% over 2020–2022), with upstaging expected for these cancer types (2, 1.4, and 6.8% for breast, cervical, and colorectal cancers, respectively). Findings for 6–12-mo disruption scenarios illustrate that maintaining screening participation is critical to preventing an increase in the burden of cancer at a population level. We provide programme-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programmes and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions.
- Open Access
The impact of COVID-19 on population cancer screening programs in Australia: modelled evaluations for breast, bowel and cervical cancer
Background: Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel and cervical cancer screening programs on cancer outcomes and cancer services. Methods: We used the Policy1 modelling platforms to estimate outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9 and 12 months. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. Results: We estimated that a 12-month screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020-2021) and colorectal cancer (up to 12·1% reduction over 2020-21), and increase cervical cancer diagnoses (up to 3·6% over 2020-2022), with upstaging expected for these cancer types. Conclusions: Findings illustrate that maintaining screening participation is critical to sustaining a reduced cancer burden. We provide program-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programs, and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions. Funding: Australian Government Department of Health
Open AccessThe impact of COVID-19 on population cancer screening programs in Australia: modelled evaluations for breast, bowel and cervical cancer
Background: Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel and cervical cancer screening programs on cancer outcomes and cancer services. Methods: We used the Policy1 modelling platforms to estimate outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9 and 12 months. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. Results: We estimated that a 12-month screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020-2021) and colorectal cancer (up to 12·1% reduction over 2020-21), and increase cervical cancer diagnoses (up to 3·6% over 2020-2022), with upstaging expected for these cancer types. Conclusions: Findings illustrate that maintaining screening participation is critical to sustaining a reduced cancer burden. We provide program-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programs, and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions. Funding: Australian Government Department of Health
- Open Access
- 8 February 2022
- Published by Elsevier in Journal of Cancer Policy
- Vol. 32, 100325
The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study
- 8 February 2022
- Published by Elsevier in Journal of Cancer Policy
- Vol. 32, 100325
Open AccessThe potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study
- 1 February 2021
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 30 (2) , 268-277
Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis
Background: Cervical screening on self-collected samples has mainly been considered for targeted use in underscreened women. Updated evidence supports equivalent sensitivity of PCR-based human papillomavirus (HPV) testing on self-collected and clinician-collected samples. Methods: Using a well-established model, we compared the lifetime impact on cancer diagnoses and deaths resulting from cervical screening using self-collected samples only, with and without the existing restriction in Australia to women aged 30+ years and ≥2 years overdue, compared with the mainstream program of 5-yearly HPV screening on clinician-collected samples starting at 25 years of age. We conservatively assumed sensitivity of HPV testing on self-collected relative to clinician-collected samples was 0.98. Outcomes were estimated either in the context of HPV vaccination (“routinely vaccinated cohorts;” uptake as in Australia) or in the absence of HPV vaccination (“unvaccinated cohorts”). Results: In unvaccinated cohorts, the health benefits of increased participation from self-collection outweighed the worst case (2%) loss of relative test sensitivity even if only 15% of women, who would not otherwise attend, used it (“additional uptake”). In routinely vaccinated cohorts, population-wide self-collection could be marginally (0.2%–1.0%) less effective at 15% additional uptake but 6.2% to 12.4% more effective at 50% additional uptake. Most (56.6%–65.0%) of the loss in effectiveness in the restricted self-collection pathway in Australia results from the requirement to be 2 or more years overdue. Conclusions: Even under pessimistic assumptions, any potential loss in test sensitivity from self-collection is likely outweighed by improved program effectiveness resulting from feasible levels of increased uptake. Impact: Consideration could be given to offering self-collection more widely, potentially as an equal choice for women. See related commentary by Lim, p. 245
- 1 February 2021
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 30 (2) , 268-277
Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis
Background: Cervical screening on self-collected samples has mainly been considered for targeted use in underscreened women. Updated evidence supports equivalent sensitivity of PCR-based human papillomavirus (HPV) testing on self-collected and clinician-collected samples. Methods: Using a well-established model, we compared the lifetime impact on cancer diagnoses and deaths resulting from cervical screening using self-collected samples only, with and without the existing restriction in Australia to women aged 30+ years and ≥2 years overdue, compared with the mainstream program of 5-yearly HPV screening on clinician-collected samples starting at 25 years of age. We conservatively assumed sensitivity of HPV testing on self-collected relative to clinician-collected samples was 0.98. Outcomes were estimated either in the context of HPV vaccination (“routinely vaccinated cohorts;” uptake as in Australia) or in the absence of HPV vaccination (“unvaccinated cohorts”). Results: In unvaccinated cohorts, the health benefits of increased participation from self-collection outweighed the worst case (2%) loss of relative test sensitivity even if only 15% of women, who would not otherwise attend, used it (“additional uptake”). In routinely vaccinated cohorts, population-wide self-collection could be marginally (0.2%–1.0%) less effective at 15% additional uptake but 6.2% to 12.4% more effective at 50% additional uptake. Most (56.6%–65.0%) of the loss in effectiveness in the restricted self-collection pathway in Australia results from the requirement to be 2 or more years overdue. Conclusions: Even under pessimistic assumptions, any potential loss in test sensitivity from self-collection is likely outweighed by improved program effectiveness resulting from feasible levels of increased uptake. Impact: Consideration could be given to offering self-collection more widely, potentially as an equal choice for women. See related commentary by Lim, p. 245